Table 5 Remaining validity of the patent corresponding to P3 certification (month)
From: Characteristics and outcomes of the drug patent linkage system in China
2021 (Second half) | 2022 | 2023 (First half) | Total | |
|---|---|---|---|---|
Total number of P3 (N) | 90 | 184 | 116 | 390 |
Median (IQR)[range], month | 19.5(15–32)[5–92] | 18(9–29)[-1-95] | 14(8-26.25)[-2-204] | 17(10-30.75)[-2-204] |
Only P3 (N) | 65 | 129 | 86 | 280 |
Median (IQR)[range], month | 17(15–31)[5–92] | 15(9–27)[-1-95] | 14(8–27)[-2-204] | 16(9.75–29.25)[-2-204] |
P3 and P2 (N) | 6 | 15 | 8 | 29 |
Median (IQR)[range], month | 60.5(59–62)[14–62] | 21(12-48.5)[7–58] | 44.5(12-45.25)[-1-46] | 45(12–49)[-1-62] |
P3 and P4 (N) | 19 | 24 | 14 | 57 |
Median (IQR)[range], month | 22(19–29)[10–75] | 14(4.5–64)[1–67] | 2(1.25–13.75)[0–23] | 15(5–27)[0–75] |
P3 and P2 and P4 (N) | 0 | 16 | 8 | 24 |
Median (IQR)[range], month | NA | 23(19.5-25.25)[18–34] | 21(18–25)[13–34] |